Results 131 to 140 of about 72,592 (256)

Phage Therapy Beyond Static Pharmaceuticals: A Framework for Controlled Evolutionary Platforms. [PDF]

Viruses
Iwano H, Fujiki J, Nakamura T.
europepmc   +1 more source

Eating Away at Antibiotic Resistance - Is Phage Therapy Our Future? [PDF]

Pathog Immun
Lederman MM, Bonomo RA.
europepmc   +1 more source

Mapping Allergen B‐ and T‐Cell Epitopes: Technological Advances and Their Role in Precision Allergy Therapy

Allergy, EarlyView.
ABSTRACT Allergic diseases arise from aberrant immune recognition of otherwise harmless environmental proteins and are driven by epitope‐specific interactions between allergens and the adaptive immune system. Although component‐resolved diagnostics have improved molecular characterisation of sensitization, they remain limited to whole‐allergen ...
Mark Møiniche, Josefine Corneliussen, Kristoffer H. Johansen, Alexandre Ruiz‐Carrasco, Caroline Paulsen, Yuchen Li, Carolina Barra, Sandhya Bangaru, Monica L. Fernández‐Quintero, Ewa Bartko, Lars Blom, Esperanza Rivera‐de‐Torre   +11 more
wiley   +1 more source

From hype to hope: reanimating phage therapy through evidence-based multidisciplinarity. [PDF]

Nat Commun
Petrović-Fabijan A, Abedon ST.
europepmc   +1 more source

Diet–Microbiome–Immune Interactions at the Gut Mucosa in Food Allergy: Mechanisms, Gaps, and Therapeutic Implications

Allergy, EarlyView.
ABSTRACT Mucosal surfaces are sites of highly dynamic interactions among epithelial and immune cells, environmental exposures, particularly dietary inputs, and the diverse microbial communities and their metabolites. These elements continually influence each other to maintain homeostasis and ensure appropriate immune discrimination between pathogens ...
Clara Delaroque, Liam O'Mahony, Inge Kortekaas Krohn, Charlotte G. Mortz, Markus Ollert, Mahesh S. Desai   +5 more
wiley   +1 more source

Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review. [PDF]

Pharmaceuticals (Basel)
Sukri A, Lopes BS, Hanafiah A.
europepmc   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Management of Diabetic Foot Infections Using Phage Therapy. [PDF]

Infect Drug Resist
Nazari M, Shokoohizadeh L.
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Phage Therapy: Targeting the Gut Microbiota for the Treatment of Acute Pancreatitis. [PDF]

J Gastroenterol Hepatol
Chen J, Duan C, Zhang K, Liu J, Han C.
europepmc   +1 more source